As per the estimates, the highest Nontuberculous Mycobacteria prevalence was recorded in the #US with 179,016 prevalent cases in 2017. There are only a few products in the later stages of clinical development in the NTM market. #Thiolanox (NOVOTERIS); #Molgradex (Savara Inc.); and #NO by Beyond Air™ are in phase II stage of development for NTM infections. To read more visit: https://www.delveinsight.com/blog/nontuberculous-mycobacteria-market/ or refer to https://www.delveinsight.com/ #market #marketresearch #pharma #biotech #lifesicence #healthcare #Mycobacteria